Comparative study of the efficacy of an induction dose of interferon-α2b with ribavirin compared with standard combined treatment in naive patients with chronic hepatitis C

Journal of Viral Hepatitis

Volumn 10, Issue 6, 2003, Pages 437-445

  Perez R ^a   Jimenez M ^b   Crespo, J ^c   Diago, M ^d   Enriquez J ^e   Vaquero, P ^f   Sola R ^g   Olcoz, J L ^h   Romero, M ⁱ   Salmeron J ^j   Blanco, Ma I ^a   Ona Ma ^a   Melon S ^a   Rodrigo, L ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^e Univ Hosp de la S Cruz y S Pablo   (Spain)

^f HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^g HOSPITAL DEL MAR   (Spain)

^h HOSPITAL DE LEÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^j HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

more..

Author keywords

Chronic hepatitis C; Comparative study; IFN alfa2b + Ribavirin; Induction dose; Naive patients

Indexed keywords

ALPHA2B INTERFERON; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ADULT; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; SPAIN; SUSTAINED VIRAL RESPONSE; THROMBOCYTOPENIA; THROMBOCYTOSIS; TREATMENT OUTCOME; VIRUS LOAD; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; RNA, VIRAL; SPAIN;

EID: 10744222689     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2893.2003.00461.x     Document Type: Article

References (41)

1. Alter MJ, Kruszon-Moran D, Nainan OV et al. The prevalence of hepatitis C virus infection in the United States, 1.998 through 1.994. N Engl J Med 1999; 341: 556-562.
2. Niederau C, Lange S, Heintges T et al. Prognosis of chronic hepatitis C: results of a large prospective cohort study. Hepatology 1998; 28: 1687-1695.
3. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patients data from European centers. J Hepatol 1997; 26: 961-966.
4. Poynard T, Leroy V, Cohard M et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24: 778-789.
5. Brouwer JT, Nevens F, Kleter B et al. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Belnelux study in 336 patients. J Hepatol 1998; 28: 951-959.
6. Karino Y, Toyota J, Sugawara M et al. Early loss of serum Hepatitis C-RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C. Am J Gastroenterol 1997; 92: 61-65.
7. Manns MP, McHutchinson JG, Gordon SC et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965.
8. Lindsay KL, Trepo Ch, Heintges T et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001; 34: 395-403.
9. Barrera JM, Bruguera M, Guadalupe-Ercilla M et al. Persistent hepatitis C viremia after acute self-limiting postransfusion hepatitis C. Hepatology 1995; 21: 639-644.
10. Hino K, Sainokami S, Shimoda K, Niwa H, Lino S. Clinical course of acute hepatitis C and changes in HCV markers. Dig Dis Sci 1994; 39: 19-27.
11. Yano M, Kumada H, Kage M et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334-1340.
12. Di Bisceglie AM, Simpson LH, Lotze MT, Hoofnagle JH. Development of hepatocellular carcinoma among patients with chronic liver disease due to hepatitis C viral infection. J Clin Gastroenterol 1994; 19: 222-226.
13. Hoofnagle JH, Mullen KD, Jones DB et al. Treatment of chronic non-A non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986; 315: 1575-1578.
14. Tiné F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B chronic hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991; 13: 192-199.
15. Reichard O, Foberg U, Fryden A et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alfa 2b for 60 weeks. Hepatology 1994; 19: 280-285.
16. Poynard T, Bedossa P, Chevallier M et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457-1462.
17. Lin R, Roach B, Zimmerman, Strasser S, Ferrell G, for the Australia Hepatitis C Study Group. Interferon alfa-2b for chronic: hepatitis C: effect of dose increment and duration of treatment on response rates. J Hepatol 1995; 23: 487-496.
18. Braconier JH, Paulsen O, Engman K, Widell A. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis 1995; 27: 325-329.
19. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 (Suppl. 2): 8-12.
20. Schalm SW, Hansen BE, Chemello L et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997; 26: 961-986.
21. Lin OS, Keeffe EB. Current treatment strategies for chronic hepatitis B and C. Ann Rev Med 2001; 52: 29-49.
22. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
23. Reichard O, Norkrans G, Frydén A et al. Randomised, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-87.
24. Poynard T, Marcellin P, Lee SS et al. Randomised trial for interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
25. Fried MW, Shiffman M, Sterling RK et al. A multicenter, randomized trial of daily high-dose interferon alfa-2b for the treatment of chronic hepatitis C: pretreatment stratification by viral burden and genotype. Am J Gastroenterol 2000; 95: 3225-3232.
26. Chan CY, Lee SD, Hwang SJ et al. Quantitative branched DNA assay and genotyping for hepatitis C virus RNA in Chinese patients with acute and chronic hepatitis C. J Infect Dis 1995; 171; 443-446.
27. Hayashi J, Ohmiya M, Kishihara N et al. A statistical analysis of predictive factors of response to human lymphoblastoid interferon in patients with chronic hepatitis C. Am J Gastroenterol 1994; 89: 2151-2156.
28. Lau JY, Mizokami M, Kolberg JA et al. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States. J Infect Dis 1995; 171: 281-289.
29. Hu KQ, Vierling JM, Redeker AG. Viral, host and interferon-related factors modulating the effect of interferon therapy for hepatitis C virus infection. J Viral Hepat 2001; 8: 1-18.
30. Iacono L. Factors that predict the response to interferon in patients with chronic hepatitis C: clinical management of individual patients. Rev Esp Enferm Dig 2000; 92: 485-494.
31. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microb Rev 2000; 13: 223-235.
32. Trepo C. Genotype and viral load as prognostic indicators in the treatment of hepatitis C. J Viral Hepat 2000; 7: 250-257.
33. Lam NP, Neumann AU, Gretch DR et al. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
34. Consensus Statement EASL. International Consensus Conference on Hepatitis C. J Hepatol 1999; 30: 956-961.
35. Lam NP, Neumann AV, Gretch DR, Wiley TE, Perelson AS, Leyden TJ. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997; 26: 226-231.
36. Zeuzem S, Schmidt JM, Lee JH, Ruster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C turnover in vivo. Hepatology 1996; 23: 366-371.
37. Neuman AU, Lam NP, Dahari H et al. Hepatitis C viral dynamics in vivo and the antiviral effect of interferon-α therapy. Science 1998; 282: 103-107.
38. Yasui K, Okaune T, Murakami Y et al. Dynamics of hepatitis C viremia following interferon-α administration. J Infect Dis 1998; 177: 1.475-1.479.
39. Bekkering FC, Brower JT, Schalm SW, Elewant A. Hepatitis C. viral kinetics (letter). Hepatology 1997; 26: 1.691-1.693.
40. Zeuzem S, Schmidt JM, Lee JH et al. virus dynamics in vivo: effect of ribavirin and interferon alpha on viral turnover. Hepatology 1998; 28: 245-252.
41. Neuman AU, Lam NP, Dahari H et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis 2000; 182: 28-35.